Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2011 3
2012 1
2013 3
2014 2
2015 6
2016 3
2017 7
2018 3
2019 11
2020 8
2021 27
2022 18
2023 22
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
Loriot Y, Kalebasty AR, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Bangs R, Tagawa ST. Loriot Y, et al. Among authors: balar av. Future Oncol. 2024 Apr 29. doi: 10.2217/fon-2023-1030. Online ahead of print. Future Oncol. 2024. PMID: 38682560 Free article. Review.
Molecular Mechanisms of Ischemic Stroke: A Review Integrating Clinical Imaging and Therapeutic Perspectives.
Rehman S, Nadeem A, Akram U, Sarwar A, Quraishi A, Siddiqui H, Malik MAJ, Nabi M, Ul Haq I, Cho A, Mazumdar I, Kim M, Chen K, Sepehri S, Wang R, Balar AB, Lakhani DA, Yedavalli VS. Rehman S, et al. Among authors: balar ab. Biomedicines. 2024 Apr 7;12(4):812. doi: 10.3390/biomedicines12040812. Biomedicines. 2024. PMID: 38672167 Free PMC article. Review.
CT Perfusion Derived rCBV < 42% Lesion Volume Is Independently Associated with Followup FLAIR Infarct Volume in Anterior Circulation Large Vessel Occlusion.
Lakhani DA, Balar AB, Salim H, Koneru M, Wen S, Ozkara B, Lu H, Wang R, Hoseinyazdi M, Xu R, Nabi M, Mazumdar I, Cho A, Chen K, Sepehri S, Hyson N, Urrutia V, Luna L, Hillis AE, Heit JJ, Albers GW, Rai AT, Dmytriw AA, Faizy TD, Wintermark M, Nael K, Yedavalli VS. Lakhani DA, et al. Among authors: balar ab. Diagnostics (Basel). 2024 Apr 19;14(8):845. doi: 10.3390/diagnostics14080845. Diagnostics (Basel). 2024. PMID: 38667490 Free PMC article.
The Relative Cerebral Blood Volume (rCBV) < 42% Is Independently Associated with Collateral Status in Anterior Circulation Large Vessel Occlusion.
Lakhani DA, Balar AB, Koneru M, Wen S, Ozkara BB, Lu H, Wang R, Hoseinyazdi M, Mei J, Xu R, Nabi M, Mazumdar I, Cho A, Chen K, Sepehri S, Hyson N, Urrutia V, Luna L, Hillis AE, Heit JJ, Albers GW, Rai AT, Dmytriw AA, Faizy T, Wintermark M, Nael K, Yedavalli VS. Lakhani DA, et al. Among authors: balar ab. J Clin Med. 2024 Mar 10;13(6):1588. doi: 10.3390/jcm13061588. J Clin Med. 2024. PMID: 38541813 Free PMC article.
CT perfusion based rCBF <38% volume is independently and negatively associated with digital subtraction angiography collateral score in anterior circulation large vessel occlusions.
Lakhani DA, Balar AB, Koneru M, Wen S, Ozkara BB, Wang R, Hoseinyazdi M, Nabi M, Mazumdar I, Cho A, Chen K, Sepehri S, Hyson N, Xu R, Urrutia V, Luna L, Hillis AE, Heit JJ, Albers GW, Rai AT, Yedavalli VS. Lakhani DA, et al. Among authors: balar ab. Neuroradiol J. 2024 Mar 25:19714009241242639. doi: 10.1177/19714009241242639. Online ahead of print. Neuroradiol J. 2024. PMID: 38528780
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Agarwal N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, Colomba E, Gravis G, Mourey L, Oudard S, Fléchon A, Gonzalez M, Maroto PM, Schweizer MT, Gallardo E, Johnston E, Balar A, Haddad N, Appiah AK, Nacerddine K, Piulats JM. Agarwal N, et al. Among authors: balar a. Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436. Online ahead of print. Clin Cancer Res. 2024. PMID: 38512117
Follow-up infarct volume on fluid attenuated inversion recovery (FLAIR) imaging in distal medium vessel occlusions: the role of cerebral blood volume index.
Salim H, Lakhani DA, Balar A, Musmar B, Adeeb N, Hoseinyazdi M, Luna L, Deng F, Hyson NZ, Mei J, Dmytriw AA, Guenego A, Faizy TD, Heit JJ, Albers GW, Urrutia VC, Llinas R, Marsh EB, Hillis AE, Nael K, Yedavalli V. Salim H, et al. Among authors: balar a. J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12279-3. Online ahead of print. J Neurol. 2024. PMID: 38507075
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, Griglun S, Leis D, Yang N, Aranchiy V, Machado S, Waalkes E, Gargano G, Soamchand N, Puranik A, Chattopadhyay P, Fedal E, Deng FM, Ren Q, Chiriboga L, Melamed J, Sirard CA, Wong KK. Wise DR, et al. Among authors: balar av. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00798-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341461
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.
Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa ST. Loriot Y, et al. Among authors: balar av. Ann Oncol. 2024 Apr;35(4):392-401. doi: 10.1016/j.annonc.2024.01.002. Epub 2024 Jan 18. Ann Oncol. 2024. PMID: 38244927 Free article. Clinical Trial.
110 results